BIOCARDIA INC BCDA 深 滬
交易中 12-24 10:04:01 美东时间
1.26
-0.010
-0.79%
華盛通- 最 高1.28
- 今 開1.28
- 成交量 651股
- 最 低 1.26
- 昨 收 1.27
- 總市值 1337.20万
- 52周最高 3.20
- 市盈率 靜 --
- 換手率 0.01%
- 52周最低 1.00
- 委 比 98.02%
- 總股本 1061.27万
- 歷史最高 129.00
- 量 比 0.18
- 振 幅 1.57%
- 歷史最低 1.00
- 每 手 1
- 風險率 0.46%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多BioCardia Completes Third Preliminary Clinical Consultation With Japan's PMDA On CardiAMP Cell Therapy Intended For Treatment Of HFrEF
BioCardia®, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announces it has completed a third preliminary clinical consultation
12-16 21:08
BioCardia Q3 EPS $(0.24) Beats $(0.25) Estimate
BioCardia (NASDAQ:BCDA) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.25) by 4 percent. This is a 60.66 percent increase over losses of $(0.61) per share from the same
11-13 05:13
BioCardia Reports Third Quarter 2025 Business Highlights and Financial Results
BioCardia reported Q3 2025 financial results and filed its 10-Q with the SEC. The company secured $6 million financing to support CardiAMP cell therapy approvals and the Helix delivery catheter submission. Clinical trials for CardiAMP in heart failure and chronic myocardial ischemia showed positive results, with ongoing enrollment in the Phase 3 CardiAMP HF II trial. The company plans a conference call to discuss these milestones.
11-12 21:40
Earnings Scheduled For November 12, 2025
Companies Reporting Before The Bell • Hudbay Minerals (NYSE:HBM) is projected t...
11-12 19:11
Earnings Outlook For BioCardia
BioCardia (NASDAQ:BCDA) is set to give its latest quarterly earnings report on ...
11-12 02:03
BioCardia shares are trading higher. The company recently announced University of Wisconsin enrolled first patient in phase 3 CardiAMP HF II cell therapy pivotal trial.
BioCardia shares are trading higher. The company recently announced University ...
10-31 23:39
BioCardia Updates ATM Offering, Raising Maximum Aggregate Sale To $5,309,253
This prospectus supplement updates and amends certain information in our base prospectus, dated December 5, 2023, as supplemented by our prospectus supplement dated December 6, 2023, as further supplemented by the
10-25 04:26
BioCardia Sets Record Date for Annual Meeting
BioCardia ( ($BCDA) ) just unveiled an announcement. BioCardia, Inc. has announ...
10-08 04:52
BioCardia regains Nasdaq compliance after balance sheet improvements; shares up
BioCardia (NASDAQ:BCDA) has regained compliance with Nasdaq listing requirements. On October 1, 2025, Nasdaq confirmed BioCardia now meets the Equity Rule. Compliance follows efforts to strengthen the...
10-02 20:23
BioCardia Regains Compliance With Nasdaq Listing Requirements
BioCardia, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announces it has regained compliance with the Nasdaq Capital Market's
10-02 20:04
